First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC
The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
Related Articles
Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer
Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.
Epirubicin/Mindfulness Intervention Improved Outcomes in Urinary Tumor Patients – Oncology Nurse Advisor
Researchers compared the effects of conventional treatment with a combination of epirubicin and mindfulness intervention on oncologic and psychologic burden in patients with urinary tract…
Pembrolizumab Provides “Robust” Clinical Benefit in Clear Cell Gynecologic Cancer
“Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
Tell Congress to reduce cancer treatment costs for patients
Tell your members of Congress to close the loophole allowing corporate hospital systems to buy local doctor’s offices and then charge patients inflated hospital prices…
70 chief strategy officers to know | 2024
Becker’s is proud to recognize 70 outstanding chief strategy officers leading hospitals and health systems in 2024.
IT and Informatics Track to focus on data strategies and success stories – Tandem Meetings News
Data standardization and interoperability, and the automation of data acquisition and transfer for research purposes will be recurring themes throughout the agenda, as explained by…
Implementing Updates to AML Classification Guidelines
Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.
Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
